Increasing Prevalence of Chronic Diseases to Augment Growth of the Biologics Market

A biologic drug
(biologics) is a product that is
produced from living organisms or contains components of living
organisms. Biologic drugs
are widely used to prevent, diagnose,
treat, or cure a variety of diseases, including infectious diseases, autoimmune
disorders, chronic kidney disease, and cancer. Biologics drugs are derived from a wide variety of
natural sources such as human, animal, or microorganisms by using biotechnology. Moreover, Biologics include a wide
variety of products such as blood and
blood components, vaccines, tissues, allergenic, gene therapy, somatic cells,
and recombinant therapeutic proteins. Novel therapies and new technologies
are emerging to create new biologics, which holds a prominent future for the
biologics market.



The market is majorly
driven by the increasing prevalence of chronic diseases across the globe, growing capital investment by key players, and
higher acceptability and increasing demand for innovative therapies. For instance, according to the National Health Council, around 157
million Americans are expected to have more than one chronic disorder
by 2020. Moreover, according to the World Health Organization,
diabetes, cancer, and cardiovascular diseases account for around 1.6 million, 9
million, and 17.9 million deaths each year, respectively.



The success of biologics in the treatment of major chronic diseases, especially autoimmune
diseases and cancer, has enabled key market players to invest in these
products. In 2019, three biologic drugs were approved by the U.S. Food and Drug
Administration, one of which is an anticoagulant solution by Griffols. Biologics
have had a higher success rate in terms of approval than conventional drugs. However,
high cost and difficulty in manufacturing (as biologics are highly complex in
nature), as well as lower availability and affordability of biologics in
middle-to-low income economies are expected to hinder the growth of the
biologics market.



In terms of geography, the biologics market is
divided into six regions, such as North America, South America, Asia Pacific,
Europe, the Middle East, and Africa. The Asia Pacific is expected to witness
substantial growth in the biologics market due to the increasing prevalence of
diabetes. Currently, the Western Pacific region alone has more than 30 million
people with diabetes. Furthermore, according to WHO, the number is expected to
increase dramatically by 2025. Government initiative for the awareness of biologics
is expected to drive the growth of the market in North America. Key players
involved in the market are focused on developing several biopharmaceutical
products to maintain the market position or strengthen their product portfolio.



Comments

Post a Comment

Popular posts from this blog

The Global Gynecological Devices Market Continues To Grow Owing To The Rising Demand For Regular Gynecological Checkups And Increasing Awareness On Women’s Health And Hygiene

Image
  A gynecological device is a medical device that is used to promote female health or to protect and preserve reproductive health for females. This is a very broad category and includes products such as watches, calculators, bandages, and hygienic towels. While many of these products have been clinically tested and found to be safe for female health, there are still a few devices in the market that pose threats to female reproductive health. Gynecological devices are usually fall into three categories: medical devices, biological safety devices, and mechanical devices. Medical devices are those that prevent the risk of injury or trauma to a woman's reproductive organs from medical interventions. Biologic safety devices are those that protect a female's health by promoting female reproductive health. Finally, mechanical devices are those that help maintain a woman's reproductive health and allow her to achieve or reach their desired fertility or pregnancy. The use of any of ...
Read more

Polyethylene Terephthalate Market Continues to Expand as British Petroleum plc signs a cooperation agreement with China Resources Chemical Materials Technology Co. Ltd to strengthen cooperation on PTA sourcing

Image
  PET is an abbreviation for polyethylene terephthalate; the material most often used in PET bottles. PET is an extremely tough plastic, which is why it's commonly used as a packaging material. PET has many advantages over other plastics, including strength, resistance to breaking and crushing, and its natural plasticity it will fill almost anything and is resistant to oil and chemicals that can cause it to break down over time. Rapid growth of the food and beverage industry is expected to drive of the global polyethylene terephthalate market growth . The food and beverage industry has witnessed significant growth in both developed and emerging economies. According to the Food and Drink Federation, the U.K., the food and drink manufacturing sector accounts for 17% in terms of economic contribution. Furthermore, according to the India Brand Equity Foundation (IBEF), the food processing industry contributed 14% of the country’s GDP in 2016. Polyethylene terephthalate or PET is widely...
Read more

Stomach Cancer Drugs Market Continues to Expand as South Korean Drug Manufacturer Celltrion Inc. Receives the WHO Prequalification Standards for its biosimilar

Image
  Stomach cancer is a growth of abnormal tissues that form a tumor in the part of your abdomen. Symptoms of stomach cancer often include persistent abdominal pain, extreme heartburn, extreme vomiting, severe indigestion, abdominal swelling, and frequent diarrhea. These symptoms are common for all forms of stomach cancer but when cancer spreads to the upper part of the chest, the symptoms become far more severe and may eventually cause death. Stomach cancer has the highest survival rate of any type of cancer in the world.  Crocetin (trade name Eulexin) is the first Stomach Cancer Drug that is used in the treatment of gastric cancer. It was later on approved for treating peritoneal mesothelioma but was not marketed extensively due to its negative outcomes at the beginning. Increasing prevalence of stomach cancer is expected to drive growth of the global stomach cancer drugs market during the forecast period. According to the American Cancer Society (ACS), in 2020, around 27,600...
Read more